<p><strong>- 展示了涵盖美学、伤口护理、骨骼和脊柱以及外科领域的主要产品线</strong> <strong>- 与来自新加坡、马来西亚、巴基斯坦、台湾和菲律宾的合作伙伴签署了总额为 53 亿韩元的供应协议</strong></p>
<p>, /PRNewswire/ -- CGBIO（首席执行官：Hyunseung Yu），一家专注于再生医学的生物技术公司，于 6 日宣布参加了最近在首尔 COEX 举行的第 41 届韩国国际医疗与医院设备展（KIMES 2026），展示了涵盖美学、伤口护理、骨骼和脊柱以及外科领域的产品，并与来自五个国家的合作伙伴签署了总额为 53 亿韩元的海外供应合同。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>CGBIO 在 KIMES 2026 上与 Neuva Era 签署了 FACETEM 在新加坡和马来西亚的独家供应协议。</p>
<p>KIMES 是一个领先的医疗设备和医院设备展览，汇聚了医疗专业人士、行业利益相关者以及国内外买家，探索最新的医疗技术和市场趋势。在今年的展览中，CGBIO 不仅专注于介绍单个产品，还通过连接其核心产品组合展示了其综合解决方案的竞争力。</p>
<p>展览的前沿是包括 FACETEM（美学）、Curasys ME（伤口护理）、NOVOSIS（骨替代品）和 CG GEL（内窥镜止血剂）在内的关键产品。</p>
<p>FACETEM 是一种胶原蛋白刺激剂，超越了传统填充剂，通过诱导体内胶原蛋白的产生，满足全球美学市场对自然体积增强和皮肤再生日益增长的重视。Curasys ME 是一种下一代负压伤口治疗（NPWT）设备，旨在兼顾医疗专业人士和患者的便利，提供更高效的伤口护理环境。NOVOSIS 以其卓越的骨诱导性能而闻名，代表了 CGBIO 在骨骼和脊柱领域的技术竞争力。CG GEL 作为一种内窥镜止血剂，通过有效控制内窥镜干预过程中的出血，展示了其在外科和程序环境中的适用性。</p>
<p>此外，CGBIO 还展示了包括 AILEENE、GISELLELIGNE、LUXX、DOOTH、Curasys2、CuraVAC 双通道、BELUNA、NOVOMAX、Verteon、EXCENDER、CUVIS-Spine、Solendos Endo Tower、Realist Bone Model、ARISTENT 和 NOVONIX 在内的多种产品。</p>
<p>在展览期间，CGBIO 通过提出反映各国特定医疗环境和合作伙伴需求的定制策略，增强了其全球市场扩展的基础。通过现场咨询，公司通过解释每条产品线的临床价值和适用性，扩大了与海外买家的互动。</p>
<p>展览期间还举行了与海外合作伙伴的签约仪式。CGBIO 与 Neuva Era 签署了 FACETEM 在新加坡和马来西亚的独家供应协议，并与 MediNova Healthcare 签署了 FACETEM 在巴基斯坦的独家分销协议。此外，公司还与 HCT Regenerative Co., Ltd.签署了 CGDerm One-Step 在台湾的供应协议，并与 Variance Trading Corporation 签署了包括 Curasys、CuraVAC、EasyFoam 和 Easydew MD Cream 在菲律宾的伤口护理解决方案产品的供应协议。</p>
<p>CGBIO 首席执行官 Hyunseung Yu 表示：“KIMES 2026 为 CGBIO 提供了展示其作为综合医疗设备解决方案提供商竞争力的机会，超越了单一产品的关注。” 他补充道：“我们将继续通过针对每个市场和合作伙伴需求的战略产品提案和合作伙伴关系，扩大我们的海外业务基础。”</p>
<p>来源 CGBIO</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA2Jk5ld3NJdGVtSWQ9Q04yNzQwNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDYyMDAwUFJfTkVXU19VU1BSX19fX19DTjI3NDA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA2Jk5ld3NJdGVtSWQ9Q04yNzQwNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDYyMDAwUFJfTkVXU19VU1BSX19fX19DTjI3NDA2"/></p>

纽交所高增长板生物技术指数 ETF - First Trust

GBIO

IBBQ

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

<p>CGBIO 是一家专注于再生医学的生物技术公司，在 2026 年 KIMES 展会上展示了其医疗设备产品组合，并与来自新加坡、马来西亚、巴基斯坦、台湾和菲律宾的合作伙伴签署了价值 53 亿韩元的供应协议。展会重点展示了 FACETEM、Curasys ME、NOVOSIS 和 CG GEL 等关键产品，强调了 CGBIO 在全球市场中的综合解决方案和竞争力。首席执行官尹贤承表示，此次活动对展示他们的全面产品和扩展针对特定市场需求的国际合作伙伴关系至关重要</p>

<p><strong>- Presented key product lines spanning aesthetic, wound care, bone and spine, and surgical fields</strong> <strong>- Signed supply agreements totaling KRW 5.3 billion with partners from Singapore, Malaysia, Pakistan, Taiwan, and the Philippines</strong></p>
<div class="lb-trans"><p><strong>- 展示了涵盖美学、伤口护理、骨骼和脊柱以及外科领域的主要产品线</strong> <strong>- 与来自新加坡、马来西亚、巴基斯坦、台湾和菲律宾的合作伙伴签署了总额为 53 亿韩元的供应协议</strong></p>
</div><p>, /PRNewswire/ -- CGBIO (CEO Hyunseung Yu), a biotechnology company specializing in regenerative medicine, announced on the 6th that it participated in the 41st Korea International Medical &amp; Hospital Equipment Show (KIMES 2026), recently held at COEX in Seoul, where it showcased products across aesthetic, wound care, bone and spine, and surgical fields, and signed overseas supply contracts worth a total of KRW 5.3 billion with partners from five countries.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- CGBIO（首席执行官：Hyunseung Yu），一家专注于再生医学的生物技术公司，于 6 日宣布参加了最近在首尔 COEX 举行的第 41 届韩国国际医疗与医院设备展（KIMES 2026），展示了涵盖美学、伤口护理、骨骼和脊柱以及外科领域的产品，并与来自五个国家的合作伙伴签署了总额为 53 亿韩元的海外供应合同。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>CGBIO signs an exclusive supply agreement with Neuva Era for FACETEM in Singapore and Malaysia at KIMES 2026.</p>
<div class="lb-trans"><p>CGBIO 在 KIMES 2026 上与 Neuva Era 签署了 FACETEM 在新加坡和马来西亚的独家供应协议。</p>
</div><p>KIMES is a leading medical device and hospital equipment exhibition that brings together healthcare professionals, industry stakeholders, and domestic and international buyers to explore the latest medical technologies and market trends. At this year's exhibition, CGBIO focused not only on introducing individual products but also on presenting its integrated solution competitiveness by connecting its core product portfolio.</p>
<div class="lb-trans"><p>KIMES 是一个领先的医疗设备和医院设备展览，汇聚了医疗专业人士、行业利益相关者以及国内外买家，探索最新的医疗技术和市场趋势。在今年的展览中，CGBIO 不仅专注于介绍单个产品，还通过连接其核心产品组合展示了其综合解决方案的竞争力。</p>
</div><p>At the forefront of the exhibition were key products including FACETEM (aesthetic), Curasys ME (wound care), NOVOSIS (bone substitute), and CG GEL (endoscopic hemostatic agent).</p>
<div class="lb-trans"><p>展览的前沿是包括 FACETEM（美学）、Curasys ME（伤口护理）、NOVOSIS（骨替代品）和 CG GEL（内窥镜止血剂）在内的关键产品。</p>
</div><p>FACETEM is a collagen stimulator that goes beyond a conventional filler by inducing collagen production within the body, addressing the global aesthetic market's growing emphasis on natural volume enhancement and skin regeneration. Curasys ME is a next-generation negative pressure wound therapy (NPWT) device designed with both medical professionals and patient convenience in mind, offering a more efficient wound care environment. NOVOSIS, known for its superior osteoinductive performance, represents CGBIO's technological competitiveness in the bone and spine segment. CG GEL, an endoscopic hemostatic agent, demonstrated its applicability in surgical and procedural settings by effectively controlling bleeding during endoscopic interventions.</p>
<div class="lb-trans"><p>FACETEM 是一种胶原蛋白刺激剂，超越了传统填充剂，通过诱导体内胶原蛋白的产生，满足全球美学市场对自然体积增强和皮肤再生日益增长的重视。Curasys ME 是一种下一代负压伤口治疗（NPWT）设备，旨在兼顾医疗专业人士和患者的便利，提供更高效的伤口护理环境。NOVOSIS 以其卓越的骨诱导性能而闻名，代表了 CGBIO 在骨骼和脊柱领域的技术竞争力。CG GEL 作为一种内窥镜止血剂，通过有效控制内窥镜干预过程中的出血，展示了其在外科和程序环境中的适用性。</p>
</div><p>In addition, CGBIO exhibited a wide range of products across various segments, including AILEENE, GISELLELIGNE, LUXX, DOOTH, Curasys2, CuraVAC Double Channel, BELUNA, NOVOMAX, Verteon, EXCENDER, CUVIS-Spine, Solendos Endo Tower, Realist Bone Model, ARISTENT, and NOVONIX.</p>
<div class="lb-trans"><p>此外，CGBIO 还展示了包括 AILEENE、GISELLELIGNE、LUXX、DOOTH、Curasys2、CuraVAC 双通道、BELUNA、NOVOMAX、Verteon、EXCENDER、CUVIS-Spine、Solendos Endo Tower、Realist Bone Model、ARISTENT 和 NOVONIX 在内的多种产品。</p>
</div><p>During the exhibition, CGBIO strengthened its foundation for global market expansion by proposing tailored strategies that reflect country-specific healthcare environments and partner needs. Through on-site consultations, the company expanded engagement with overseas buyers by explaining the clinical value and applicability of each product line.</p>
<div class="lb-trans"><p>在展览期间，CGBIO 通过提出反映各国特定医疗环境和合作伙伴需求的定制策略，增强了其全球市场扩展的基础。通过现场咨询，公司通过解释每条产品线的临床价值和适用性，扩大了与海外买家的互动。</p>
</div><p>Contract signing ceremonies with overseas partners were also held during the exhibition period. CGBIO signed exclusive supply agreements with Neuva Era for FACETEM in Singapore and Malaysia, and with MediNova Healthcare for exclusive distribution of FACETEM in Pakistan. Additionally, the company entered into a supply agreement with HCT Regenerative Co., Ltd. for CGDerm One-Step in Taiwan, and with Variance Trading Corporation for wound care solution products including Curasys, CuraVAC, EasyFoam, and Easydew MD Cream in the Philippines.</p>
<div class="lb-trans"><p>展览期间还举行了与海外合作伙伴的签约仪式。CGBIO 与 Neuva Era 签署了 FACETEM 在新加坡和马来西亚的独家供应协议，并与 MediNova Healthcare 签署了 FACETEM 在巴基斯坦的独家分销协议。此外，公司还与 HCT Regenerative Co., Ltd.签署了 CGDerm One-Step 在台湾的供应协议，并与 Variance Trading Corporation 签署了包括 Curasys、CuraVAC、EasyFoam 和 Easydew MD Cream 在菲律宾的伤口护理解决方案产品的供应协议。</p>
</div><p>Hyunseung Yu, CEO of CGBIO, stated, &#34;KIMES 2026 served as an opportunity for CGBIO to demonstrate its competitiveness as a comprehensive medical device solution provider, moving beyond a single-product focus.&#34; He added, &#34;We will continue to expand our overseas business foundation through strategic product proposals and partnerships tailored to the needs of each market and partner.&#34;</p>
<div class="lb-trans"><p>CGBIO 首席执行官 Hyunseung Yu 表示：“KIMES 2026 为 CGBIO 提供了展示其作为综合医疗设备解决方案提供商竞争力的机会，超越了单一产品的关注。” 他补充道：“我们将继续通过针对每个市场和合作伙伴需求的战略产品提案和合作伙伴关系，扩大我们的海外业务基础。”</p>
</div><p>SOURCE CGBIO</p>
<div class="lb-trans"><p>来源 CGBIO</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA2Jk5ld3NJdGVtSWQ9Q04yNzQwNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDYyMDAwUFJfTkVXU19VU1BSX19fX19DTjI3NDA2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN27406&amp;Transmission_Id=202604062000PR_NEWS_USPR_____CN27406&amp;DateId=20260406"/></p>

20:00 ETCGBIO Showcases Comprehensive Medical Device Portfolio at KIMES 2026 Achieves KRW 5.3 Billion in Contract Results

prnewswire

Generation Bio

Invesco Nasdaq Biotechnology ETF

ETCGBIO 在 KIMES 2026 上展示了其全面的医疗设备产品组合，并取得了 53 亿韩元的合同成果